Trial Profile
Phase II study of antineoplastons A10 and AS2-1 in patients with primitive neuroectodermal tumor outside the central nervous system
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2017
Price :
$35
*
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 28 Sep 2005 New trial record.